ARM · Arm Holdings plc — research history

Extreme valuation (129x Fwd P/E, 395x EV/EBITDA) and active FTC regulatory overhang leave no margin of safety or mispricing edge. Material insider selling ($8.5M) and pipeline anti-signals for dilution/accounting further trigger mandatory skip protocols.

Extreme valuation (129x Fwd P/E, 395x EV/EBITDA) and active FTC regulatory overhang leave no margin of safety or mispricing edge. Material insider selling ($8.5M) and pipeline anti-signals for dilution/accounting further trigger mandatory skip protocols.

ARM has experienced extraordinary 137% YTD gains driven by agentic AI infrastructure optimism and strong licensing momentum (+29% growth). The stock sits within 7.5% of its all-time high at an extremely rich forward P/E of 129x (vs sector median ~25-30x) and EV/EBITDA of 395x. Insider filings reveal zero open-market purchases — all recent Form 4s trace to scheduled RSU vesting, option exercises, or pre-arranged 10b5-1 sales by CFO Jason Child at sub-$200 levels; Richard Grisenthwaite (Chief Architect) sold vested shares at $209 on May 18. Brad Gerstner's Altimeter Capital opened a ~$259M position in Q1 2026 but the stock has since traded above that cost basis. The FTC is actively investigating ARM's licensing practices as the company moves into chip manufacturing — a material regulatory risk with no resolution timeline. Earnings on July 29 represent the next near-term catalyst. Options flow shows an 80% call-side directional bias with multiple whale OTM blocks, corroborating bullish sentiment but not adding fundamental edge.

Extreme valuation (124x Fwd P/E) and an active FTC investigation leave zero margin of safety, while material insider selling and a lack of discretionary buying negate smart-money support. The Agentic AI tailwind is fully priced in, making this dossier fall well below the publish threshold.

ARM's bullish signals are concentrated in options flow (44% net $ call bias on Jul-17 expiry) and a notable new 13F-initiation by Brad Gerstner's Altimeter Capital ($259M position opened Q1 2026). However, reading every Form 4 filed in the past 30 days reveals that all insider activity is either RSU vesting/exercise (A/M codes), scheduled selling under pre-set Rule 10b5-1 plans, or routine tax-withholding on equity compensation — zero open-market purchases by executives. The CFO sold ~$7.2M of shares at $180-$227 via 10b5-1 plans, well below current prices. Valuation is extreme (124x forward P/E, 379x EV/EBITDA) with the stock near its 52-week high of $427.99 and trading 11% off that peak on a BofA catalyst day. A live FTC investigation adds regulatory risk to the licensing model at exactly the moment ARM is expanding into chip manufacturing.

Extreme valuation (129x Fwd P/E), unambiguous insider selling ($25M), and an active FTC investigation into its core licensing model create a bearish setup with multiple anti-signal gates (dilution, low liquidity). No viable trade structure fits the risk profile.

The Form 4 cluster trigger proves to be entirely executive SELLING (S-code transactions, cash-out of positions), not buying. Multiple C-suite officers — the CCO sold ~$5M face value in three weeks, the CPO liquidated her entire remaining position at $288-291, the CLO dumped nearly his full holding at $215, and the CFO executed scheduled 10b5-1 selling. Combined with a newly opened FTC investigation into Arm's licensing model (June 3), extreme valuation (129x forward P/E, 410x EV/EBITDA), RSI at 74.4, and analyst target of $247 vs current ~$395 — the setup is unambiguously bearish for bullish structured ideas. The stock has run +268% YTD with no insider support; every signal points in the opposite direction from what triggered this investigation.

Arm is at an all-time high of $344 with +154% YTD gain. The Form 4 cluster that triggered investigation resolves to routine RSU vestings (directors) and scheduled Rule 10b5-1 sales by C-suite executives — zero open-market purchases from anyone in a conviction-buying position. Fundamentals are genuinely strong (97%+ gross margins, dominant IP licensing franchise, AI infrastructure tailwinds with AGI CPU launch), but forward P/E of ~113x and EV/EBITDA of 300x leave no mispricing cushion whatsoever. The FTC antitrust probe announced May 16 adds regulatory uncertainty at precisely the worst moment for valuation re-rating. Technical RSI of 76.4 confirms extreme overbought conditions atop a parabolic move.

All 16 Form 4 filings in the last two weeks are routine RSU vesting events (code M) with associated tax withholding disposals (code F) from a single May 15, 2026 vest date across ~14 insiders/executives — zero open-market purchases were made. The investigation trigger was a false signal; there is no smart-money cluster in the traditional sense. ARM hit an all-time high of $291.62 on May 21 after Nvidia's bullish Vera CPU commentary, giving it a +88.5% YTD return and a forward P/E of ~95x with EV/EBITDA near 234x — extreme multiples even for a premium semiconductor IP licensor. A live FTC antitrust investigation adds regulatory risk to the licensing model while an S-8 shelf registration enables further ESOP dilution.

Extreme valuation (72x Fwd P/E, 214x EV/EBITDA) leaves zero margin of safety, and all recent insider activity is selling. Combined with anti-signal flags for concentration/dilution and a lack of mispricing, this dossier fails to support any trade structure.

Arm is a world-class licensing business with strong fundamentals — near-monopoly CPU architecture, 97%+ gross margins, 29.6% operating margin, and accelerating revenue from AI/data-center demand. However the stock at $220 trades at 72x forward P/E and 214x EV/EBITDA, both extremes versus peers. All insider activity in the past 90 days is selling via pre-planned Rule 10b5-1 programs (no discretionary open-market buys). The June 2026 call whale flow (68% net $ bullish bias, +$5M notional) confirms speculative appetite but does not constitute smart-money conviction. KeyBanc recently raised the PT to $300 on AI momentum — a typical sell-side price-target raise that often coincides with late-stage bull runs. Arm is approaching its 52-week high ($239.50 vs current $220), leaving little upside buffer before earnings on July 29, 2026.

Extreme valuation, persistent insider selling, and bearish put skew leave no structural edge. Active anti-signal gates (SoftBank's ~90% ownership concentration and dilution overhang) present unacceptable governance and liquidity risks, warranting a skip.

Arm reported Q4 FY2026 earnings on May 7, 2026 — beat estimates but the stock fell ~11% in a single session. The bearish reaction was triggered by smartphone royalty weakness overshadowing record licensing revenue, plus CEO Rene Haas flagging supply constraints on its new AI data-center CPU (Neoverse N2). Forward P/E of 99x and EV/EBITDA of 229x are extreme relative to semis peers; the stock is fully priced for a best-case AI ramp scenario. Zero insider open-market purchases in 90 days — all Form 4s show pre-scheduled 10b5-1 selling by CEO (Rene Haas) and CFO (Jason Child). Options IV is elevated (~75% ATM at Jun 12), creating premium collection opportunity but no structural edge on a directional long.